

Tracleer® (bosentan) is an orally active dual endothelin receptor antagonist (ERA). Tracleer® works by blocking the binding of endothelin (ET) to both ETA and ETB receptors, preventing the deleterious effects of endothelin.
Since its introduction in the USA (2001), EU (2002) and other countries worldwide, Tracleer® has become the cornerstone therapy for PAH.



